Enzo Biochem (ENZ) Akcie Kurz
Enzo Biochem Kurz
Za posledních 19 let vzrostly tržby Enzo Biochem o 18,4 % ročně a dosáhly 992,90 Mil. USD. Zisk na akcii klesal o 30,0 % ročně za posledních 5 let. U Enzo Biochem je čistá marže -0,8 % dolů oproti 6,7 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 18,20 %.
Cena akcie Enzo Biochem
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Enzo Biochem a analýza akcií
Nejčastější otázky týkající se akcie Enzo Biochem
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.
The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.
Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.
Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.
Enzo Biochem Inc is primarily present in the United States.
Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.
5 analytiků aktuálně hodnotí akcii Enzo Biochem: 4 doporučuje koupit, 1 držet a 0 prodat. Pro rok 2026 analytici očekávají u Enzo Biochem tržby 107,03 Mil. USD a zisk na akcii -0,07 USD.
Při aktuálním kurzu se akcie Enzo Biochem obchoduje za 0,49 EUR (0,55 USD).
Akcie Enzo Biochem (ENZ) je kótována na 6 burzách, mimo jiné: NYSE (ENZ), London (0IHV.L), SIX (Zürich) (EZB.SW), Frankfurt (EZB.F), München (EZB.MU), Düsseldorf (EZB.DU).
Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.
Tržby očekávané za Enzo Biochem činí 107,03 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Enzo Biochem činí -9,72 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Enzo Biochem je aktuálně -7,85. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Enzo Biochem.
Poměr ceny k tržbám (P/S) Enzo Biochem je aktuálně 0,71. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Enzo Biochem.
Score kvality pro Enzo Biochem je 6/10.
ISIN Enzo Biochem je US2941001024. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Enzo Biochem je 865607. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Enzo Biochem je ENZ. Symbol tickeru se používá k obchodování akcií Enzo Biochem na burze.
Enzo Biochem akcie
Enzo Biochem Peer Group
Enzo Biochem Ticker
Enzo Biochem FIGI
Všechny fundamentální údaje o Enzo Biochem v podrobné analýze
Naše analýzy akcií společnosti Enzo Biochem zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Enzo Biochem. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: